James E. Fickenscher
2014 - Antares Pharma
In 2014, James E. Fickenscher earned a total compensation of $227.5K as Chief Financial Officer at Antares Pharma.
Compensation breakdown
| Option Awards | $183,795 |
|---|---|
| Salary | $43,750 |
| Total | $227,545 |
Fickenscher received $183.8K in option awards, accounting for 81% of the total pay in 2014.
Fickenscher also received $43.8K in salary.
Rankings
In 2014, James E. Fickenscher's compensation ranked 12,255th out of 13,032 executives tracked by ExecPay. In other words, Fickenscher earned more than 6.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 12,255 out of 13,032 | 6th |
Division Manufacturing | 4,676 out of 4,966 | 6th |
Major group Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks | 682 out of 736 | 7th |
Industry group Surgical, Medical, And Dental Instruments And Supplies | 409 out of 446 | 8th |
Industry Surgical and Medical Instruments and Apparatus | 251 out of 275 | 9th |
Source: SEC filing on April 22, 2016.
Fickenscher's colleagues
We found four more compensation records of executives who worked with James E. Fickenscher at Antares Pharma in 2014.
News
Zynerba Pharmaceuticals CEO Armando Anido's 2022 pay slips 15% to $1.9M
April 21, 2023
Zynerba Pharmaceuticals CEO Armando Anido's 2021 pay jumps 49% to $2.2M
April 25, 2022
Zynerba Pharmaceuticals CEO Armando Anido's 2020 pay rises 8% to $1.5M
April 21, 2021
Zynerba Pharmaceuticals CEO Armando Anido's 2019 pay falls 32% to $1.4M
April 23, 2020
Zynerba Pharmaceuticals CEO Armando Anido's 2018 pay slips 18% to $2M
April 25, 2019